100% Quality Guarantee
PhD-Level Technical Support
Human TP63 Recombinant Protein (N-His)
Key Features

Human TP63 Recombinant Protein (N-His) (GXRP02856)

SKU GXRP02856
Product Type Recombinant Protein
Species Human
Expression System E. coli
Tag N-His
$458 - $2,412

Request a formal quotation

A PDF quote with its own quote number, ready for your purchasing office to raise a PO against. Back within 4 working hours, from a PhD scientist — not an autoresponder.

  • PO-ready PDFQuote number, VAT, Incoterms
  • Volume pricing appliedDiscounts from 2 kits up
  • Valid 30 daysPrices held while you get sign-off
Anything we should know? optional

No account needed. We use your details only to prepare and send this quote. If it's urgent, say so in the box and we'll come back the same working day.

Global Shipping: 80+ Countries
White Glove Service: Available upon request
Batch Consistency: Contact Sales
Distributors: 60+ Countries

Description

system_update_altDatasheetsystem_update_altMSDS

Human TP63 Recombinant Protein (N-His)

Human TP63 Recombinant Protein (N-His) is a recombinant protein expressed in E. coli, spanning Ser41-Cys339, with an N-terminal His tag. Predicted molecular weight: 35.54 kDa. Purity: >90% as determined by SDS-PAGE. Supplied lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1 mM EDTA, 4% Trehalose, 1% Mannitol. Applications: ELISA, immunogen, SDS-PAGE and Western blot. Tumor protein 63 (TP63/p40) is a ~76 kDa protein. Acts as a sequence specific DNA binding transcriptional activator or repressor. For research use only.

The isoforms contain a varying set of transactivation and auto-regulating transactivation inhibiting domains thus showing an isoform specific activity. Isoform 2 activates RIPK4 transcription. May be required in conjunction with TP73/p73 for initiation of p53/TP53 dependent apoptosis in response to genotoxic insults and the presence of activated oncogenes. Involved in Notch signaling by probably inducing JAG1 and JAG2.

View AllClose

0 Reviews

0
Based on 0 reviews

No reviews yet. Be the first to share your experience!

View AllClose